It was a stark assertion by the patient leader. Stark because, while an entirely reasonable suggestion, it is historically unheard of in a system built on an institutional framework that instinctively and habitually protects and serves its own interest. …
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News